

Mankind Pharma

BSE SENSEX 77,496 **S&P CNX** 24,178

CMP: INR2,257 TP: INR2,640 (+17%)

Buy



Stock Info

Bloomberg	MANKIND IN
Equity Shares (m)	413
M.Cap.(INRb)/(USD\$b)	931.7 / 9.8
52-Week Range (INR)	2727 / 1910
1, 6, 12 Rel. Per (%)	4/0/-11
12M Avg Val (INR M)	1201
Free float (%)	27.3

Financials Snapshot (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	142.7	161.0	180.6
EBITDA	35.3	41.4	47.7
Adj. PAT	18.9	26.6	30.7
EBITDA Margin (%)	24.7	25.7	26.4
Cons. Adj. EPS (INR)	45.8	64.4	74.3
EPS Gr. (%)	-1.6	40.7	15.4
BV/Sh. (INR)	381.3	427.0	482.3

Ratios

Net D:E	0.2	0.0	-0.1
RoE (%)	12.6	15.9	16.3
RoCE (%)	11.1	13.1	15.5
Payout (%)	19.1	18.4	19.3

Valuations


P/E (x)	49.3	35.0	30.4
EV/EBITDA (x)	28.6	23.7	20.0
Div. Yield (%)	0.4	0.5	0.6
FCF Yield (%)	6.1	5.6	5.9
EV/Sales (x)	7.1	6.1	5.3

Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	72.7	72.7	72.7
DII	14.5	13.3	11.5
FII	10.2	11.3	12.9
Others	2.6	2.8	2.9

FII Includes depository receipts

Stock Performance (1-year)



Domestic formulation on revival mode; BSV scaling up

- Mankind’s domestic formulation (DF) business is witnessing a healthy revival, with Mar’26 growth at 11.5% YoY vs. IPM growth at 10.6% (1.1pp outperformance). The broad-based recovery in DF is driven by chronic therapies (cardiac up ~20%/anti-diabetic up ~12.6% YoY), indicating improving execution and field force stability after restructuring.
- Growth drivers are strengthening structurally, with the performance of new Rx launches surging 4.8x over the past three years (to INR5.2b in MAT Mar’26) and a concentrated contribution from top brands (~65%). Moreover, a rapidly scaling up in-licensed/partnered portfolio (~3x growth, led by respiratory) is building a dual-engine growth model for Mankind.
- BSV has moved past the integration phase, with a strong pickup in growth in 3QFY26 (20%+ YoY), driven by normalization in operations and improved execution. With cost synergies having largely been realized, the next phase will be led by revenue synergies, cross-selling opportunities and operating leverage.
- On overall basis, we expect a CAGR of 13%/11% in DF/export revenue over FY26-28, led by restructuring-led revival and strengthening revenue synergy in acquired products. Accordingly, we expect 16% EBITDA CAGR over FY26-28. This would be further supported by a declining interest outgo, driving 27% earnings CAGR over FY26-28. We value Mankind at 35x 12M forward earnings to arrive at a TP of INR2,640. Reiterate BUY.

DF: Broad-based recovery with chronic strength and pipeline-driven growth acceleration

- Mankind’s Mar’26 performance (~11.5% YoY vs. IPM’s ~10.6%) marks a clear revival, indicating ~1.1pp outperformance and signaling a strong exit momentum after a prolonged phase of underperformance, driven by restructuring and operational disruptions over the past 12-15 months.
- The recovery is broad-based but quality-led, anchored by chronic therapies cardiac/anti-diabetic (up ~20%/12.6% YoY) and supported by selective acute traction, while anti-infectives remain a key laggard (-0.4%).
- The rebound in Mar’26 is driven by core brands, with Glizid-M (+25% YoY), Telmikind (+21% YoY), and Dydroboon (+20% YoY) anchoring growth. Meanwhile, Cefakind/Gudcef continue to lag.
- In the past three years, the performance of new launches surged ~4.8x to INR5.2b, with top 20% brands contributing ~65%. Growth is non-linear/therapy-driven – Gastro leads with ~8x; anti-diabetic compounds steadily by 3-4x; and AI/Pain therapies show strong ramp-up from a lower base.

BSV: Integration behind, growth acceleration driven by execution and synergies

- BSV’s performance in 1HFY26 was impacted by integration-related disruptions, with sequential improvement through the period indicating steady normalization in operations.
- Growth accelerated meaningfully from 3QFY26 (20%+ YoY), led by both domestic specialty and export segments, reflecting a recovery in execution.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Vipul Mehta (Vipul.Mehta@MotilalOswal.com) | **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- The prescription business has already surpassed full-year FY25 sales within 9MFY26, underscoring the strength of the rebound.
- Cost synergies and operational efficiencies are largely in place, supporting improved productivity and margin expansion.
- With integration largely behind and revenue synergies gaining traction, BSV is well positioned to deliver sustainable double-digit growth.

Valuation and view


- We expect Mankind to deliver ~13% revenue CAGR over FY26-28, led by a recovery in DF, steady traction in chronic therapies, and strong growth from new product launches and brand extensions across key segments.
- Growth will be further supported by the integration of the BSV acquisition, with revenue synergies beginning to materialize through portfolio cross-leverage, expanded reach in women's health and fertility segments, and improved field-force productivity.
- EBITDA/PAT are expected to clock ~16%/~27% CAGR over FY26-28, driven by steady gross margin expansion owing to premiumization and scale benefits from acquired businesses.
- We value the company at ~35x 12M forward earnings, reflecting improving growth visibility, strong domestic franchise execution, and synergy realization from acquisitions. **Maintain BUY with a TP of INR2,640.**

DF Rx (ex-BSV): Strengthening core therapies while expanding into high-growth chronic segment

DF Rx (ex- BSV) segment completes restructuring, enters growth phase

- Mankind's growth in Mar'26 (~11.5% YoY vs. IPM's ~10.6%) marks a clear revival, translating into ~1.2x outperformance.
- This is particularly significant as it represents a healthy revival, signaling that growth has likely bottomed out and early signs of re-acceleration are emerging.
- The improvement suggests that underlying demand traction and execution have strengthened, **making Mar'26 a potential turning point after a period of subdued performance in 3QFY25.**

Exhibit 1: Mar'26 signals emerging growth around story



Source: MOFSL, Company


- The outperformance is more meaningful when viewed in the context of the past 12-15 months, marked by operational disruptions and restructuring-led challenges.
- During this phase, the company undertook field force realignment and portfolio rationalization, which temporarily impacted productivity and led to underperformance vs. IPM in the last five quarters.
- Additionally, factors such as supply chain disruptions (including GST-related changes) and weakness in acute therapies further weighed on growth, particularly in 2QFY26/3QFY26.
- With these corrective actions now largely behind, the stabilization of the field force and improving execution intensity are beginning to reflect in monthly performance. **The strong Mar'26 print, thus, indicates green shoots of recovery, suggesting that Mankind is transitioning from a restructuring phase to a more stable, execution-led growth trajectory.**

Cardiac/Anti-Diabetic/VMN/Gastro/Gynaec outperform; Respiratory/Anti-Infectives underperform

- At a therapy level, the Mar'26 outperformance (Mankind's ~11.5% vs. IPM's ~10.6%) was broad-based across key therapies, indicating improving traction. Growth was led by Cardiac (~20% YoY), followed by VMN (~15.8% YoY), Gastro (~14.2% YoY), Gynaec (~13.1% YoY), and Anti-diabetic (~12.6% YoY), reflecting strong momentum across both chronic and select acute segments.

- However, some pockets continue to lag, with Anti-infectives declining ~0.4% and Respiratory growing modestly by ~5.7%, indicating that parts of the acute portfolio remain under pressure.

Exhibit 2: Therapy wise growth trends in Mar'26 (vs IPM)



Source: MOFSL, Company

Telmikind/Glizid-M lead chronic surge; Dydroboon adds momentum, while Cefakind/Gudcef remain soft

- Mankind's top 10 brands present a mixed but evolving growth narrative as of Mar'26.

Exhibit 3: Performance of Top 10 brands in Mar'26

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
Total		121,558	8.2	100.0	8.7	11.5
Manforce	Urology	5,958	10.4	72.1	6.4	10.5
Moxikind-Cv	Anti-Infectives	4,076	4.5	11.4	-0.8	1.2
Amlokind-At	Cardiac	2,998	9.8	39.4	5.5	7.0
Unwanted-Kit	Gynaec.	2,562	3.2	57.0	-6.6	-6.1
Prega News	Others	2,476	8.1	82.6	28.7	13.5
Dydroboon	Gynaec.	2,404	8.2	17.2	20.3	20.3
Telmikind-Am	Cardiac	2,116	22.8	15.3	18.4	21.0
Gudcef	Anti-Infectives	2,084	1.7	17.3	-6.6	-7.4
Glimestar-M	Anti Diabetic	2,060	5.0	5.6	-2.2	-3.9
Candiforce	Derma	2,024	2.0	19.6	0.0	9.0


- The Mar'26 revival ~11.5% YoY growth is clearly reflected at the brand level, with recovery being driven by core brands aligned to high-growth therapies. In cardiac (~20% therapy growth), flagship brands such as Telmikind-AM/ Telmikind delivered strong double-digit momentum ~21%YoY, offset by a drag in AMLOKIND-AT ~7% YoY.
- Similarly, anti-diabetic growth of ~12.6% YoY was supported by growth in Glizid-M (~25.5% YoY), partially offset by a decline in GLIMESTAR-M.
- The portfolio continues to be led by Manforce, which retains a commanding position in urology with ~72% market share and has delivered steady double-digit growth of ~10.5% YoY.

- Among acute therapies, recovery was selective but visible, with Dydroboon (~20.8% YoY) driving gynaecology, partially offset by weak performance in Unwanted kit. Gastro saw slight improvement, led by Nurokind-LC (12% YoY).
- However, anti-infectives remained a drag (-0.4%), with key brands such as Cefakind/Gudcef/Gudcef-CV showing relatively weaker traction, reflecting continued pressure in the segment.
- Overall, the performance underscores that recovery is being led by strong brands in chronic therapies and select acute pockets, while parts of the portfolio remain uneven, indicating that a fully broad-based recovery is still evolving.

Transition phase underway: Volume-led recovery gains traction as acute portfolio drags

- Mankind’s growth trajectory over the past four years reflects a phase of moderation, followed by early signs of recovery, particularly visible in the most recent period. While the company initially outpaced IPM, the differential narrowed in FY24/FY25 due to internal disruptions and portfolio recalibration.
- **On an annualized basis, DF growth appears to have lagged the guided ~1.2x IPM benchmark.**

Exhibit 4: IPM vs. Mankind YoY growth (%) trends over MAT Mar’23 to Mar’26



Source: IQVIA, MOFSL, Company

- Notably, the growth mix is undergoing a structural shift, with price-led expansion and moderation in incremental contributions from new launches. **Volume has started growing, indicating a transition toward a more demand-driven growth profile.**

Exhibit 5: Growth mix evolution of Mankind; shift toward volume-led recovery


Growth Driver (%)	MAT Mar’24	MAT Mar’25	MAT Mar’26	Comments
Volume	-1.1	0.3	2.3	Inflecting
Price	6.3	4.4	4.2	Normalizing
New Launches	3.2	2.8	1.6	Tapering

Source: IQVIA, MOFSL, Company

- Chronic therapies have been the key growth driver, with Mankind broadly tracking industry momentum. While it sustained outperformance over IPM in MAT Mar’24/Mar’25, the gap has narrowed sharply in MAT Mar’26, with growth largely in line with the industry (~13.4% vs ~13.6%).


- In contrast, the acute portfolio continues to lag. After marginal outperformance in MAT Mar’24, Mankind’s growth slipped below IPM in MAT Mar’25 and the gap widened further in MAT Mar’26, with subdued growth of 5.3% (IPM’s 7.5%).

Exhibit 6: IPM vs. Mankind chronic growth



Source: IQVIA, MOFSL, Company

Exhibit 7: IPM vs. Mankind acute growth



Source: IQVIA, MOFSL, Company

Strong launches in past three years with select high-impact winners

- The performance of Mankind’s newly launched portfolio over the last three years has surged from INR1.1b in MAT Mar’24 to INR5.2b in MAT Mar’26 (~120% CAGR), indicating an aggressive and successful launch engine at an aggregate level.
- Mankind’s recent launches reflect a well-structured concentration pattern where value creation is led by a select set of high-performing brands.
- **While the classic 80/20 rule suggests that ~80% of outcomes stem from ~20% of inputs, Mankind’s portfolio exhibits a more even distribution with the top ~20% brands contributing ~INR3.4b (~65%), a far more balanced distribution than a sharp 80/20 skew.**
- Among launches in past three years, the top 5% brands contribute ~INR1.7b (~30% value) and the top 10% account for ~50% value, underscoring Mankind’s ability to consistently build and scale up high-impact brands.
- This concentration, rather than being a weakness, highlights a disciplined focus on “big wins”, where the long tail (~60%+ brands <INR20m) should be viewed as a strategic pipeline for future scaling, providing a broad base of optionality from which the next set of winners can emerge.

Exhibit 8: Pareto analysis of new launches over past three years

Segment	Brands	MAT Mar’26 (INRb)	Value (%)	Comments
Top 5% (Cumulative)	8	1.7	~30%	❖ Strong anchor
Top 10%(Cumulative)	16	2.5	~50%	❖ Core growth layer
Top 20% (Cumulative)	32	3.4	~65%	❖ Majority monetization (but not extreme)
Rest (~80%)	128	1.8	~45%	❖ Broad but fragmented

Source: MOFSL, Company

Multi-therapy; winner-led launch engine driving non-linear but sustained brand expansion

- The top ~20% of Mankind’s new launch brands over past three years (contributing ~65% of portfolio value) reflect a multi-therapy, multi-velocity growth construct rather than a uniform scale-up.
- Within Gastro therapy, VONALONG/NOBEL SPAS NEW delivered 3x/5x growth over MAT Mar’25 to Mar’26.
- In contrast, earlier launches such as Ranidom Raft/Pilorute-EP show maturing trajectories, with growth moderating after initial uptake with market share gains stabilizing at low-to-mid single digits.
- Within anti-diabetic therapy, NobeGlar expanded from INR75m to INR210m (~2.8x growth) with a gradual improvement in market share from 0.7% to 1.6%, indicating steady but persistent penetration in a competitive insulin market.
- Notably, SGLTD-Trio has scaled to INR200m (~4x from base), though with some moderation in share momentum, suggesting early saturation in initial prescriptions.
- Within Respiratory therapy, Codistar-NF delivered 2-yr CAGR of ~16%, but largely plateaued between MAT Mar’25 and MAT Mar’26, indicating a stabilizing leadership base after the initial scale-up.
- In contrast, Asthakin Pro has been the standout growth driver, expanding ~4.6x over MAT Mar’24-Mar’26 reflecting strong prescription-led adoption. Meanwhile, CombiHale-G/lpralungs are emerging contributors, gradually scaling from a low base.
- Meanwhile, anti-infectives/pain therapies show strong ramp-up from low bases.

Exhibit 9: Analysis of top 20% brands launched over past three years

Therapy	Key brands	MAT Mar’24 (Value INRm)	MAT Mar’26 (Value INRm)	Growth (x)	Market share Insights
Gastro	Vonalong, Nobel Spas New, Raft brands	~115	~900	~8x	❖ Fastest scaler; Vonalong/Nobel Spas each ~INR210m, strong early share gains 8%/17%
Anti-diabetic	SGLTD-Trio, Dynaduo, Nobeglar GLIPTAGREAT DM	~180	~840	~3.6x	❖ Market share <3% of NOBEGLAR/ SGLTD-TRIO~INR200m each.
Respiratory	Codistar-NF, Asthakin Pro, CombiHale-G	~410	~715	~1.7x	❖ Market share Codistar-NF MS/ Asthakin Pro ~16.5/15%
Anti-infective	Polizkta, Gudcef AV, Rifasmart	~0	~180	NA	❖ High early-cycle ramp, Market share of POLIZKTA~8%
Pain	Nimulid Strong, Polmaforce	~25	~155	~6x	❖ Faster MS (%) ramp up to 9% for POLMAFORCE ~INR50m
VMN	Ossopan-XT	~15	~45	~3x	❖ Slow-moving market share

Source: MOFSL, Company

In-licensed/partnered portfolio: Small base, high-impact growth engine

- Currently, the in-licensed portfolio’s scale-up from ~INR400m in MAT Mar’24 to ~INR1150m in MAT Mar’26 (~3x growth) indicates that with a small base, it is rapidly scaling.
- Within Cardiac therapy, Crenzlo stood out, scaling up to ~INR94m with ~15% MS/~2.5x growth over MAT Mar’25 to Mar’26, indicating early category leadership in the inclisiran segment.

- Within Gastro, Vonalong has been the fastest-scaling asset, reaching ~INR215m with ~8.4% MS (%) / 3x growth over MAT Mar'25 to Mar'26, highlighting strong prescription adoption.
- The Respiratory portfolio is scaling up as a dual-engine franchise, with Symbicort growing steadily (~INR323m, ~2% MS) and Combihale-G ramping up from lower base (~INR65m, ~2% MS), delivering ~1.6x growth over MAT Mar'25 to Mar'26.
- In Anti-diabetic therapy, Nobeglar has scaled up to ~INR210m (~2.8x growth), reflecting a gradual but steady penetration in the insulin segment. In Derma; Daffy (~INR21.5m) provides a stable, moderate-growth base.
- These products are leveraged via existing field force/doctor outreach channels, expanding the therapeutic offering. Despite minimal contribution ~2% of Rx sales, they require minimal incremental investment, making them asset-light, high-efficiency growth levers.

Exhibit 10: In-licensed/partnered portfolio sales over MAT Mar'24 to Mar'26

Brands	Therapy	Indication	Value (INRm)	Value (INRm)	MS (%)	
			MAT MAR'24	MAT MAR'26	MAT MAR'26	
SYMBICORT #FY24	Respiratory	COPD / Asthma	200	323	2	❖ Exclusive distribution agreement with AstraZeneca for India
DAFFY #FY22	Derma	Infant skin & hair care	123	215	1	❖ acquired from DRRD
VONALONG #FY25	Gastro	GERD / Acid-related disorders	0	215	8	❖ In-licensed from Takeda
NOBEGLAR #FY23	Anti-diabetic	Type 1/Type 2 Diabetes	75	210	2	❖ In-licensed from Biocon, to foray in niche insulin category
CRENZLO #FY25	Cardiac	High LDL Cholesterol	0	94	15	❖ In-licensed from Novartis
COMBIHALE-G #FY22	Respiratory	COPD / Inhalation therapy	1	65	2	❖ acquired from DRRD, to foray into the inhaler market.
VONATIME #FY25	Gastro	GERD / Acid-related disorders	0	39	2	❖ In-licensed from Takeda
NEPTAZ-D #FY22	Cardiac	Heart Failure	0	6	1	❖ In-licensed from Novartis


Source: IQVIA, MOFSL, Company

BSV: Integration phase behind, growth acceleration ahead

Transition from integration phase to visible growth inflection

- BSV's performance in 1HFY26 was largely shaped by integration-related disruptions, including M&A transition, organizational restructuring, and a weak base in late FY25, resulting in subdued YoY growth.
- 1Q/2QFY26 growth remained in the mid to high single-digit range YoY; however, sequential performance improved meaningfully with double-digit QoQ growth, indicating gradual normalization in operations.
- Management undertook corrective measures during this phase, including leadership changes in the domestic business and restructuring of the prescription portfolio to improve execution intensity.
- By 2QFY26, key integration initiatives across supply chain, procurement, and overhead rationalization were largely completed, stabilizing the operating base.
- **3QFY26 marked an inflection point, with growth accelerating to 20%+ YoY**, driven by strong traction in both domestic specialty and international markets.

Exhibit 11: BSV YoY growth recovered in 3Q



Source: MOFSL, Company

- The **prescription business surpassing FY25 sales within 9MFY26** underscores the sharp recovery in demand and execution post-integration.

Synergy realization largely complete; revenue synergies to drive next leg


- A significant portion of cost synergies has already been realized by 2QFY26, particularly across supply chain optimization, raw material sourcing efficiencies, vendor renegotiations, and corporate overhead rationalization.
- BSV's portfolio inherently carries a high gross margin profile, with over 70% contribution from mandate brands, providing a strong foundation for operating leverage as scale improves.
- Field force productivity has improved meaningfully, with **PCPM increasing to INR1.3m (TTM Sep'25) from INR1.1m earlier**, reflecting enhanced commercial efficiency and better portfolio focus.
- Mankind's extensive pan-India distribution network and strong doctor engagement are expected to significantly enhance penetration of BSV's specialty products across fertility clinics, institutional channels, and Tier 2/3 markets.

- **Cross-selling opportunities across complementary therapy** areas such as women’s health, fertility, and critical care are likely to drive incremental revenue growth over the medium term.
- With cost synergies largely captured, the next phase of value creation is expected to be driven by **revenue synergies, mix improvement, and operating leverage**.

Strategic fit enhances Mankind’s positioning in high-barrier specialty segments

- The acquisition of BSV significantly **strengthens Mankind’s presence in high entry-barrier segments** such as women’s health, fertility, immunoglobulins, recombinant biologics, and critical care.
- These segments are characterized by complex manufacturing processes, stringent regulatory requirements, and limited competition, enabling structurally superior margins and sustainable growth visibility.
- BSV brings a differentiated portfolio with strong presence across 12 of the top 15 global infertility molecules, alongside niche offerings such as recombinant Anti-D and other biologics.
- The combined entity is well positioned to **offer end-to-end solutions across the women’s health lifecycle**, from fertility treatment to post-pregnancy care, enhancing its competitive positioning.
- Structural tailwinds, including low IVF penetration (below 1% in India and emerging markets), rising infertility rates, delayed parenthood, and increasing affordability, provide significant long-term growth headroom.
- Ongoing **investments in biologics manufacturing capacity (INR1.5-2b)** are expected to support future scale-up, improve supply chain resilience, and reduce dependence on existing facilities.


Exhibit 12: Mankind to drive end-to-end value chain growth with BSV



Source: MOFSL, Company


Story in charts

Exhibit 13: Expect 12.5% sales CAGR over FY26-28




Source: Company, MOFSL

Exhibit 1: Expect 12.4% CAGR in DF (Ex-BSV) sales over FY26-28




Source: Company, MOFSL

Exhibit 14: Expect export (ex-BSV) sales CAGR of 12.4% over FY26-28




Source: Company, MOFSL

Exhibit 15: EBITDA margin to expand to ~26.4% by FY28




Source: Company, MOFSL

Exhibit 16: Expect EPS CAGR of ~27.4% over FY26-28



Source: Company, MOFSL

Exhibit 17: ~ROE to revive over FY27-28 (%)



Source: Company, MOFSL

Financials and valuations

Mankind Pharma - Income Statement							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total sales	77,816	87,490	103,348	122,480	142,681	161,035	180,640
Change (%)	25.2	12.4	18.1	18.5	16.5	12.9	12.2
Total Expenditure	57,922	67,201	77,997	91,698	107,427	119,649	132,951
% of Sales	74.4	76.8	75.5	74.9	75.3	74.3	73.6
Gross Profit	53,598	58,354	71,251	87,537	102,198	114,335	128,254
EBITDA	19,894	20,289	25,351	30,782	35,254	41,386	47,689
Margin (%)	25.6	23.2	24.5	25.1	24.7	25.7	26.4
Depreciation	1,666	3,259	3,983	6,212	8,949	9,306	9,447
EBIT	18,227	17,030	21,368	24,570	26,305	32,080	38,242
Int. and Finance Charges	586	445	335	4,294	6,325	3,943	3,586
Other Income	1,960	1,286	2,809	5,368	3,242	3,239	3,658
PBT bef. EO Exp.	19,602	17,871	23,842	25,644	23,222	31,376	38,313
EO Items	0	1,275	0	-830	1,066	0	0
PBT after EO Exp.	19,602	16,597	23,842	26,474	24,288	31,376	38,313
Total Tax	5,216	3,616	4,576	5,097	3,922	6,777	8,511
Tax Rate (%)	26.6	21.8	19.2	19.3	16.1	21.6	22.2
Minority Interest	50	162	137	79	219	137	186
Reported PAT	14,335	12,819	19,129	21,297	18,015	24,462	29,616
Adjusted PAT	14,335	13,816	19,129	19,188	18,882	26,568	30,655
Change (%)	12.1	-3.6	38.5	0.3	-1.6	40.7	15.4
Margin (%)	18.4	15.8	18.5	15.7	13.2	16.5	17.0

Balance sheet							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Share Capital	401	401	401	413	413	413	413
Other equity	61,152	73,952	93,230	142,911	156,912	175,762	198,605
Net Worth	61,552	74,352	93,631	143,324	157,324	176,175	199,017
Minority Interest	1,611	1,881	2,127	2,358	2,139	2,002	1,816
Total Loans	8,680	1,626	1,960	84,830	59,830	29,830	14,830
Deferred Tax Liabilities	163	475	87	17,046	17,998	17,998	17,998
Other Non-Current Liabilities	1,031	1,557	2,050	2,512	2,927	3,303	3,705
Capital Employed	73,038	79,892	99,855	250,071	240,219	229,309	237,367
Gross Block	42,261	52,149	59,078	145,210	146,710	148,710	151,210
Less: Accum. Deprn.	6,638	9,897	13,879	20,091	29,041	38,346	47,794
Net Fixed Assets	35,623	42,253	45,199	125,119	117,669	110,364	103,416
Goodwill on Consolidation	204	200	200	64,926	64,926	64,926	64,926
Capital WIP	7,015	5,501	2,818	8,257	8,257	8,257	8,257
Total Investments	11,149	14,619	26,027	22,423	22,423	22,423	22,423
Other Non-Current Assets	1,770	1,759	1,483	2,818	3,282	3,704	4,155
Curr. Assets, Loans&Adv.	35,324	32,491	43,101	52,974	55,728	56,268	75,283
Inventory	17,602	14,985	15,535	20,937	25,409	28,678	33,654
Account Receivables	3,882	5,764	8,483	15,383	16,809	18,089	19,796
Cash and Bank Balance	4,059	4,532	11,980	5,545	9,965	5,500	17,345
Loans and Advances	9,780	7,210	7,104	11,109	3,545	4,002	4,489
Curr. Liability & Prov.	18,046	16,931	18,973	26,446	32,068	36,634	41,094
Account Payables	10,764	10,082	11,030	11,334	14,464	16,765	18,806
Other Current Liabilities	4,638	2,999	2,819	6,922	8,064	9,101	10,209
Provisions	2,645	3,849	5,124	8,189	9,540	10,767	12,078
Net Current Assets	17,277	15,560	24,128	26,529	23,661	19,634	34,189
Appl. of Funds	73,038	79,892	99,855	250,071	240,219	229,309	237,367

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)							
EPS	35.8	34.5	47.8	46.5	45.8	64.4	74.3
Cash EPS	39.9	42.6	57.7	61.6	67.5	86.9	97.2
BV/Share	153.7	185.6	233.7	347.4	381.3	427.0	482.3
DPS	0.0	0.0	9.6	10.3	8.7	11.9	14.4
Payout (%)	0.0	0.0	20.0	22.2	19.1	18.4	19.3
Valuation (x)							
P/E	63.0	65.4	47.2	48.5	49.3	35.0	30.4
Cash P/E	56.5	52.9	39.1	36.6	33.4	25.9	23.2
P/BV	14.7	12.1	9.6	6.5	5.9	5.3	4.7
EV/Sales	11.5	10.4	8.7	7.5	7.1	6.1	5.3
EV/EBITDA	45.2	44.8	35.5	29.9	28.6	23.7	20.0
Dividend Yield (%)	NA	NA	0.4	0.5	0.4	0.5	0.6
FCF per share	-35.5	25.7	45.9	47.6	103.0	93.6	99.9
Return Ratios (%)							
RoE	26.4	20.3	22.8	16.2	12.6	15.9	16.3
RoCE	24.7	19.6	22.8	14.9	11.1	13.1	15.5
RoIC	35.0	25.1	24.8	12.0	9.2	10.9	13.1
Working Capital Ratios							
Asset Turnover (x)	1.1	1.1	1.0	0.5	0.6	0.7	0.8
Inventory (Days)	69	68	54	54	59	61	63
Debtor (Days)	18	24	30	46	43	41	40
Creditor (Days)	50	42	39	34	37	38	38
Leverage Ratio (x)							
Net Debt/Equity	-0.1	-0.2	-0.4	0.4	0.2	0.0	-0.1

Cash Flow statement

(INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	19,746	16,712	23,994	25,248	23,222	31,376	38,313
Depreciation	1,666	3,259	3,983	6,212	8,949	9,306	9,447
Interest & Finance Charges	321	445	330	4,040	6,325	3,943	3,586
Direct Taxes Paid	-4,995	-3,231	-4,795	-5,668	-3,922	-6,777	-8,511
(Inc)/Dec in WC	-5,861	1,667	204	-1,464	7,237	-484	-2,759
CF from Operations	10,877	18,852	23,714	28,368	41,812	37,364	40,077
Others	-1,679	-719	-2,190	-4,234	2,176	3,239	3,658
CF from Operating incl EO	9,198	18,133	21,524	24,134	43,988	40,603	43,735
(Inc)/Dec in FA/IA	-23,424	-7,830	-3,147	-4,488	-1,500	-2,000	-2,500
Free Cash Flow	-14,226	10,303	18,377	19,646	42,488	38,603	41,235
(Pur)/Sale of Investments	4,921	-1,892	-17,388	-5,471	0	0	0
Others	4,811	-819	388	-1,16,277	-3,242	-3,239	-3,658
CF from Investments	-13,691	-10,541	-20,147	-1,26,236	-4,742	-5,239	-6,158
Increase in equity capital				29,632	0	0	0
Inc/(Dec) in Debt	6,242	-6,978	315	73,782	-25,000	-30,000	-15,000
Interest Paid	-178	-419	-262	-981	-6,325	-3,943	-3,586
Dividend paid				0	-4,233	-5,749	-6,960
Others	-18	278	6,687	-6,766	733	-137	-186
CF from Fin. Activity	6,046	-7,119	6,740	95,668	-34,826	-39,828	-25,733
Inc/Dec of Cash	1,553	472	8,118	-6,435	4,420	-4,465	11,844
Opening Balance	1,273	4,059	4,532	11,980	5,545	9,965	5,500
Closing Balance	2,826	4,532	12,650	5,545	9,965	5,500	17,345
Total Cash & Cash Eq	4,059	4,532	11,980	5,545	9,965	5,500	17,345

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< - 10\%$
NEUTRAL	$< - 10\%$ to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motalal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motalal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motalaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motalaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motalaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motalaloswal.com
Mr. Ajay Menon	022 40548083	am@motalaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motalaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motalaloswal.com

Registration details of group entities.: Motalal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motalal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motalaloswal.com. In case of grievances for any of the services rendered by Motalal Oswal Financial Services Limited (MOFSL) write to grievances@motalaloswal.com, for DP to dpgrievances@motalaloswal.com.